Mackenzie Financial’s Sutro Biopharma STRO Stock Holding History

Mackenzie Financial’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.15M	Buy	+94,767	New	+$2.95M	﹤0.01%	943

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Mackenzie Financial's STRO Position: Q2 2026 in Review

Mackenzie Financial opened a new position in Sutro Biopharma (STRO) in Q2 2026: 94,767 shares worth $3.15M. The stake represents ﹤0.01% of the portfolio and ranks #943 among its holdings.

100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Mackenzie Financial held 94,767 shares of Sutro Biopharma worth $3.15M as of Q2 2026.
Sutro Biopharma was a new Mackenzie Financial position in Q2 2026.
Sutro Biopharma made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #943 holding.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.